Fig. 5.

Analysis of TILT-123 detection and tumor transduction in post-treatment biopsies. A Number of patients per biopsy site grouped by presence of TILT-123 in day 8 biopsies as assessed by qPCR or IHC. Only patients with results available for both assays were included. B Number of patients per biopsy site grouped by signs of tumor transduction. Signs of tumor transduction were assessed using tumor qPCR, IHC or mIF results and only patients with results available for at least two of the assays were included. C Percentage of patients showing signs of tumor transduction per individual trial and cross-trial. D Association of OS and positive TILT-123 detection (n = 8) or negative TILT-123 detection (n = 6) in day 8 biopsies as assessed by qPCR or IHC. Groups were compared using log-rank (Mantel-Cox) test where *p < 0.05